Translational meeting
3-4 June 2024, Stockholm, Sweden
Translational science – from bench to bedside ↓
Frontiers in precision medicine for peripheral vascular disease
This meeting aims to merge basic researchers, physicians and industry to give scientific updates on burning issues.
Oral abstract presentations and posters with Young Investigator Awards
in collaboration with
and 
REGISTRATION
Registration is currently open!
On the morning of June 3d, 8.00-11.00, the ESVS Translational Spring meeting organizes two work-shops for young trainees/scientists. Both work-shops accept approximately 20 participants, participation is free and reserved to ESVS Translational Spring Meeting participants but pre-registration is necessary.
WORKSHOPS
Registration is currently open!
Accommodation
There is a wide range of hotels in the area of the venue, please find below some suggestions:
Elite Hotel Carolina Tower: 160€ – in front of the venue
Blique by Nobis: 135€ – 9min walk
Hotel Bema: 120€ – 25min walk (bus possible)
Best Western Plus Park City Solna: 85€ – 25min walk (bus possible)
Venue
Bioclinicum
Auditorium Sune Bergstrom
Solnavägen 30
171 64 Solna
Sweden
Accreditation
The ESVS Translational Meeting, taking place from 3rd to 4th June, 2024 in Stockholm, Sweden has applied for European CME credits (ECMEC®s) to the European Accreditation Council for
Continuing Medical Education (EACCME®).
Directions
From Arlanda airport:
Flygbussarna Airport Coaches, direction Stockholm, stop at Solna Solnavagen (35min)
32min by taxi
From Bromma airport:
Flygbussarna Airport Coaches, direction Stockholm Central Train Station, stop at Stockholm Fridhemsplan, then bus 77 direction Karolinska sjukhuset, stop at Karolinska Institutet Biomedicum (39 min) – 15min by taxi
PROGRAMME
3 June, 2023
08:00-11:00
Biobanking workshop (Ljubica Matic, Sweden, Sanela Kjellquist, Sweden)
Image processing workshop (Anton Razuvaev, Sweden, Joy Roy, Sweden)
11:00-12:00 – Registration+Sandwich/Coffee
| Time | Presentation type | Presentation Title | Speakers/Moderators |
| 12.00 | Introductory remarks | Ulf Hedin, Sweden | |
| 12.10 | Session 1: Phenotyping disease – from lesion biology to imaging | Ulf Hedin, Sweden | |
| 12.10 | Clinical introduction | Unmet clinical needs: What does precision medicine mean in PVD? | Anna Martling, Sweden/Ulf Hedin, Sweden |
| 12.25 | Keynote lecture 1 | Precision medicine for aneurysms | Lars Maegdefessel, Germany |
| 12.45 | Keynote lecture 2 | Individualized management of atherosclerotic disease | Ulf Hedin, Sweden |
| 13.05 | Abstract presentation | 18F-NAF PET-MRI in patients undergoing carotid endarterectomy – correlation with ex vivo imaging and histology. | Jakub Kaczynski, UK |
| 13.15 | Abstract presentation | A novel porcine thoracic aortic aneurysm model reveals persistently elevated matrix metalloproteinase activity in aneurysmal tissues | Bryan Tillman, US |
| 13.25 | Abstract presentation | The transcriptome of increased finite element analysis-derived rupture risk in abdominal aortic aneurysms | Moritz Lindquist Liljeqvist, Sweden |
| 13.35 | Abstract presentation | Semaglutide prevents aortic Dissection and rupture in angiotensin II-infused apolipropotein e deficient Mice | Amanda Balboa Ramilo, Sweden |
| 13.45 | Concluding remarks/Discussion | ||
| 14.00 | Poster session 1/Coffee break | ||
| 15.00 | Session 2: Genetics in risk prediction | Anton Razuvaev, Sweden | |
| 15.00 | Clinical introduction | Unmet clinical needs: Why I care about the family history of my patients | Gert de Borst, The Netherlands |
| 15.15 | Keynote lecture 1 | Genetic risk in AAA | Maria Sabater Lleal, Spain |
| 15.35 | Keynote lecture 2 | Precision medicine through human genomics | Minna Kaikkonen, Finland |
| 15.55 | Abstract presentation | Decoding aortic disease genomic variants using stem cell models | Aminder Singh, UK |
| 16.05 | Abstract presentation | FOXC1 controls smooth muscle cell phenotypic modulation in vascular disease in response to thyroid hormone | Sofija Vuckovic, Sweden |
| 16.15 | Abstract presentation | Differential expression of long non-coding RNAs in thoracic aortic disease | Joscha Buech, Germany |
| 16.25 | Abstract presentation | The natural history of ascending aortic aneurysms involve infiltration of lipoproteins and immune cells | David Freiholtz, Sweden |
| 16.35 | Concluding remarks/Discussion | ||
| 17.00 | Poster Session 2 | Riikka Tulamo, Finland/Rebecka Hultgren, Sweden | |
4 June, 2023
| Time | Presentation type | Presentation Title | Speakers/Moderators |
| 08.00 | Session 3: Biomarkers in risk prediction | Ljubica Matic, Sweden/ Ulf Hedin, Sweden | |
| 08.00 | Clinical introduction | Unmet clinical needs: Where can we improve patient selection? | Jes Lindholt, Denmark |
| 08.15 | Keynote lecture 1 | Imaging biomarkers for aneurysms | Rachael Forsythe, UK |
| 08.35 | Keynote lecture 2 | Plasma biomarkers for unstable atherosclerosis | Manuel Mayr, UK |
| 08.55 | Abstract presentation | Blood proteins are associated with aneurysm growth in men with screening detected abdominal aortic aneurysm | Siika Antti, Sweden |
| 09.05 | Abstract presentation | Analyses of biomechanical differences to predict rupture risk in infrarenal aortic aneurysms | Kristina Grassl, Austria |
| 09.15 | Abstract presentation | Why is lipidomics important in abdominal aortic aneurysm: evidence of altered lipid profile | Helena Beatriz Ferreira, Portugal |
| 09.25 | Abstract presentation | A biomarker profile to predict amputation-free survival in patients with chronic limb threatening ischemia | Andreea Luciana Rata, Romania |
| 09.35 | Concluding remarks/Discussion | ||
| 09.50 | Poster session 3/Coffee break | Riikka Tulamo, Finland/Rebecka Hultgren, Sweden | |
| 10.50 | Session 4: Computational medicine | David Marlevi, Sweden/Joy Roy, Sweden | |
| 10.50 | Clinical introduction | Unmet clinical needs: When I think my lap-top will do a better job | Scott Berceli, USA |
| 11.00 | Invited lecture 1 | Application of artificial intellegence for patients with PAD | Juliette Raffort, France |
| 11.15 | Invited lecture 2 | Predicting aneurysm growth | Regent Lee, UK |
| 11.30 | Invited lecture 3 | Machine learning algorithms in risk prediction for patients with CLTI | Katharine McGinigle, USA |
| 11.45 | Invited lecture 4 | ||
| 12.00 | Abstract presentation | Tailored risk assessment and forecasting in intermittent claudication – a proof of concept decision support tool | Ravindhran Bharadhwaj, UK |
| 12.10 | Abstract presentation | Use of natural language processing for identification of aortic dissection on radiology reports – Petticoat study. Feasibility phase. | Powezka Katarzyna, UK |
| 12.20 | Abstract presentation | Interaction between subclinical carotid atherosclerosis endotype and biological sex: a study from improve cohort | Qiao Sen Chen, Sweden |
| 12.20 | Concluding remarks/Discussion | ||
| 12.40 | Poster Session 4/Lunch | Riikka Tulamo, Finland | |
| 14.00 | Session 5: Clinical implementation | Carl Wahlgren Sweden | |
| 14.00 | Clinical introduction | Unmet clinical needs: What do I want from basic science? | Joakim Nordanstig, Sweden |
| 14.10 | Invited lecture 1 | Automated aneurysm segmentation | Gregoire Avignon, France |
| 14.25 | Invited lecture 2 | Endovascular thrombectomy: The INDIAN Trial | Edoardo Pasqui, Italy |
| 14.40 | Invited lecture 3 | Intelligent AV grafts for hemodialysis : The TELEGRAFT Study | Jes Lindholt, Denmark |
| 14.55 | Abstract presentation | Histology-based validation of artificial intelligence-assisted peripheral arterial disease lesion classification from 9.4 tesla magnetic resonance images | Csore Katrin, US |
| 15.10 | Abstract presentation | Targeting Mir29b in a porcine model of aortic aneurysm disease: a novel endovascular treatment option | Hanft Katrin, Germany |
| 15.20 | Abstract presentation | Preconditioning with tetrahydrobiopterin improves outcome after spinal cord ischemia in a small animal model | Heidler Juliana, Austria |
| 15.30 | Abstract presentation | Short-term Carboloading promotes angiogenesis in the lower limb in a mouse model of hindlimb ischemia | Bechelli Clémence, Switzerland |
| 15.30 | Concluding remarks/Discussion | ||
| 15.50 | Prize ceremony for best abstract, poster and oral presentation | ||
| 16.00 | Farewell remarks/Adjourn | ||
